SVB Wealth LLC Buys Shares of 41,388 Hims & Hers Health, Inc. (NYSE:HIMS)

SVB Wealth LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 41,388 shares of the company’s stock, valued at approximately $1,001,000.

Other large investors have also made changes to their positions in the company. Quest Partners LLC grew its position in Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after acquiring an additional 807 shares during the last quarter. Stonekeep Investments LLC boosted its stake in shares of Hims & Hers Health by 5.5% in the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after purchasing an additional 882 shares in the last quarter. Principal Securities Inc. grew its holdings in shares of Hims & Hers Health by 48.2% during the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after purchasing an additional 1,002 shares during the last quarter. Cadent Capital Advisors LLC increased its position in Hims & Hers Health by 1.5% during the 4th quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock worth $1,745,000 after purchasing an additional 1,060 shares in the last quarter. Finally, Raleigh Capital Management Inc. lifted its stake in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other news, insider Michael Chi sold 7,259 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $32.25, for a total transaction of $234,102.75. Following the completion of the sale, the insider now owns 184,947 shares in the company, valued at $5,964,540.75. The trade was a 3.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares in the company, valued at $9,549,268.05. The trade was a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,062,011 shares of company stock valued at $36,892,724 in the last quarter. 17.71% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on HIMS shares. BTIG Research began coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Leerink Partners upped their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday, February 25th. Bank of America lifted their price target on Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research note on Thursday, February 20th. Canaccord Genuity Group upped their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Finally, Needham & Company LLC raised their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $37.23.

Hims & Hers Health Trading Down 9.8 %

Shares of HIMS opened at $40.65 on Tuesday. The firm’s fifty day simple moving average is $36.83 and its two-hundred day simple moving average is $26.99. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98. The stock has a market capitalization of $9.03 billion, a P/E ratio of 92.39 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.